See the DrugPatentWatch profile for novarel
Ferring Pharmaceuticals offers Novarel, a brand name for human chorionic gonadotropin (hCG) [1]. Novarel is used in assisted reproductive technologies to stimulate ovulation in women undergoing fertility treatment and to increase sperm count in men [1].
How is Novarel used in fertility treatments?
In women, Novarel is administered to trigger the final maturation of the egg follicle and induce ovulation. It is typically given 24 to 36 hours before an egg retrieval procedure in conjunction with in vitro fertilization (IVF) [1]. In men, Novarel can be used to treat hypogonadotropic hypogonadism, a condition characterized by low levels of sex hormones, by stimulating testosterone production [1].
What is the active ingredient in Novarel?
The active ingredient in Novarel is human chorionic gonadotropin (hCG) [1]. hCG is a hormone naturally produced during pregnancy that plays a crucial role in reproductive processes [1].
Can Novarel be used for pregnancy testing?
While Novarel contains hCG, it is not used for pregnancy testing. Pregnancy tests detect hCG in urine or blood to confirm pregnancy [2]. Novarel is a prescription medication for specific medical uses in fertility treatment [1].
When does Novarel's patent protection end?
Information regarding the specific patent expiry for Novarel is not publicly available in the provided context. Drug patent information can be complex and is often tracked by specialized services [3]. For detailed patent timelines, resources like DrugPatentWatch.com can provide specific data [3].